Vieworks Co Ltd

Vieworks maintains a conservative capital structure with a debt-to-equity ratio of 0.28, below the industry median of 0.45, and holds 29.6 billion KRW in cash and equivalents. However, free cash flow turned negative at -5.7 billion KRW in the latest period, driven by capital expenditures of -29.4 billion KRW. The company's liquidity risk is rated as medium due to net cash being negative after subtracting total debt. Profitability metrics show a return on equity of 8.8%, exceeding the industry median of 6.5%, and a return on assets of 6.24%, above the median of 4.8%. Gross margin of 42.1% (100.9 billion KRW gross profit on 239.3 billion KRW revenue) aligns with the industry median of 41.5%. Operating margin of 9.1% (21.7 billion KRW operating income) is 150 basis points above the sector average. Geographically, Vieworks derives 92% of revenue from South Korea, with the remaining 8% from Asia-Pacific markets. Product concentration is high in CT systems, which account for 85% of total revenue. No material revenue is disclosed from therapeutic equipment or software services. Revenue growth accelerated to 18.2% year-over-year in FY2024, driven by increased CT scanner installations in regional hospitals. Analysts project 12.5% revenue growth in FY2025, with operating income expected to expand 14.3% as production efficiency improves. The company's capex intensity remains elevated at 12.3% of revenue, reflecting ongoing R&D investments in AI-enhanced imaging systems. Risk assessment identifies liquidity as the primary concern, with cash balances insufficient to cover long-term debt of 69.9 billion KRW. Dilution risk is low, supported by no recent share issuance and diluted shares outstanding matching basic shares at 8.97 million. No material regulatory risks are disclosed in the latest filings. Recent 10-K filings disclose a 2025-01 regulatory review of medical device safety protocols in South Korea. The company also announced a 2024-09 partnership with Seoul National University Hospital to develop AI diagnostic tools for CT scans. No material earnings call transcripts are available for the last 90 days.